VANCOUVER, Feb. 4 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), a specialty pharmaceutical company focused on drug-eluting medical devices and biomaterials, today announced the appointment of Gary Ingenito, MD, PhD to Senior Vice President, Clinical Development & Regulatory Affairs, effective immediately.
Dr. Ingenito brings over 17 years of experience in clinical and regulatory affairs having held executive positions in large- and medium-sized pharmaceutical companies as well as clinical research organizations. He joins the Company from SFBC International, a major contract research organization acting as Senior Vice President. Prior to joining SFBC, Dr. Ingenito was Chief Operating Officer at Otsuka Maryland Research Institute of Otsuka Pharmaceuticals where he was responsible for clinical and regulatory strategy for programs involving the central nervous system, cardiovascular, pulmonary, gastroenterology, endocrine and ophthalmology. His position at Otsuka included extensive involvement with the US Food and Drug Administration. Prior to Otsuka, Dr. Ingenito held the position of Executive Director, Clinical Research at Corning Besselaar overseeing the international development of pharmaceuticals. He has also held senior positions with Sandoz Pharmaceuticals focusing on strategic plans for national and international clinical trials. Dr. Ingenito received a PhD from Thomas Jefferson University, an MD from Jefferson Medical College and a BA from Johns Hopkins University. He completed his post-graduate residency at the University of Miami.
"We are thrilled with the addition of Dr. Ingenito to our management team," said William Hunter, MD, MSc, President and CEO of Angiotech. "He brings a distinguished record of clinical development and impressive knowledge of regulatory affairs that will be vital as we execute on our pipeline and continue to revolutionize medical device and biomaterial interventions."
Dr. Ingenito will provide strategic insight, leadership and direction for the company's worldwide clinical development and regulatory activities.
Additional biographical detail on Angiotech's senior management is available on the Company website at http://www.angiotech.com/.
Vancouver-based Angiotech Pharmaceuticals, Inc., a specialty pharmaceutical company focusing on drug-eluting medical devices and biomaterials, is dedicated to enhancing the performance of medical devices and biomaterials through the innovative uses of pharmacotherapeutics. To find out more about Angiotech Pharmaceuticals, Inc. please visit our website at http://www.angiotech.com/
Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continue," "estimate," "expects," "may" and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with the United States Securities and Exchange Commission or the Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements.
CONTACTS:
Todd Young, Angiotech Pharmaceuticals (Analysts & Investors),
(604) 221-7676 ext 6933
Rui Avelar, Angiotech Pharmaceuticals, Inc. (Analysts),
(604) 221-7676 ext 6996
Eric Starkman, Starkman & Associates (Media), (212) 252-8545 ext 12
Angiotech Pharmaceuticals, Inc.